ProKidney Pharma (PROK): רווח נקי למניה (EPS TTM)

ProKidney Corp. (PROK) is developing a unique cell therapy for kidney regeneration, where success depends on FDA approval. The annual earnings per share trend reflects the current state of the business, with the parameter stabilizing at -0.54. While a personalized approach to treatment is establishing a new standard in nephrology, the lack of ready-made products temporarily deprives the company of pricing power.

Trailing twelve-month earnings per share (EPS TTM) reflects the actual efficiency of capital generation per share of the business, isolating the financial result from the impact of the total number of securities. By analyzing the current annual earnings per share, an investor assesses the ability of ProKidney Corp. (PROK) to fund the development of cell therapy for kidney restoration without excessive equity dilution.